Muhammad Umair Bakhsh, MD
Cardiovascular Disease (Cardiology) · Clovis
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
- Since medical school
- 18 years
- Graduated 2008
Offices
5 locations · Fresno Community Hospital and Medical Center · Community Foundation Medical Group · Saint Agnes Medical Center
Hospitals listed: Clovis Community Medical Center · Community Regional Medical Center · Saint Agnes Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bakhsh’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A134291 · Current
Licensed to practise in California · since 2015 · expires 2028-06-30 · University of Health Sciences Lahore, Rawalpindi Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Cardiovascular Disease
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Interventional Cardiology
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
- Saint Agnes Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.312, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.141, Oct 2024 – Sep 2025
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Saint Agnes Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.312 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.141 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.18 to 1.94) · 2,342 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 197.82 (152.64 to 243.01) · 103 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 300 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 768 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 969 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 304 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 4,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.42) · 11,641 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 12,213 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.76 (2.91 to 6.61) · 2,466 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.49) · 864 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.61 (0.26 to 2.96) · 2,362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.1 (5.39 to 14.81) · 900 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.4 (1.2 to 7.59) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.41 to 3.27) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.67 (0.14 to 1.19) · 9,626 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 58 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.835 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.004 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,002 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 28.8 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.5 · 894 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.8 · 981 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 1,061 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.4 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 412 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.6 to 15.9) · 1,324 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 863 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 32% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$274,706
Medicare paid this office $274,706 for 531 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 37 | $45,114 | $1,219 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 232 | $38,442 | $161 |
| Short return visit (20+ min) | 282 | $31,570 | $73 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 37 | $30,182 | $408 |
| New patient visit (45+ min) | 190 | $22,557 | $119 |
See all 19 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 37 | $45,114 | $1,219 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 232 | $38,442 | $161 |
| Short return visit (20+ min) | 282 | $31,570 | $73 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 37 | $30,182 | $408 |
| New patient visit (45+ min) | 190 | $22,557 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 99 | $20,436 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 114 | $16,149 | $135 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 58 | $11,754 | $203 |
| Return visit (30+ min) | 105 | $10,017 | $94 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 14 | $5,108 | $365 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 17 | $4,701 | $277 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 298 | $3,373 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 47 | $2,914 | $57 |
| Critical care, first 30-74 minutes | 14 | $2,627 | $164 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 36 | $2,083 | $56 |
| New patient visit (30+ min) | 18 | $1,477 | $82 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 14 | $1,008 | $36 |
| Injection, regadenoson, 0.1 mg | 46 | $806 | None |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 78 | $765 | $9 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 16 | More than 41% of doctors who do this |
| Pacemaker insertion or repair | 1-10 | None |
Who their Medicare patients are
531 Original Medicare patients in 2024. Average age 75 · Under 65 5% · 85 and older 14% · Women 51% · Also on Medicaid 23% · Health risk score 1.47. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 53% · Diabetes 44% · Chronic kidney disease 38% · Heart failure 32% · Atrial fibrillation 29% · Depression 21% · COPD 16% · Cancer 15% · Stroke 12% · Dementia 9%.
The office billed $1,191,443, Medicare allowed $351,212 and paid $274,706; for 2,396 services of 59 kinds; $858 of it was for drugs given in the office and $273,847 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 531 | 2,396 | 75 | 1.47 | $1,191,443 | $274,706 |
| 2023 | 395 | 1,372 | 72 | 2.57 | $330,374 | $81,378 |
| 2022 | 362 | 1,370 | 73 | 2.70 | $322,083 | $83,948 |
| 2021 | 184 | 338 | 74 | 2.82 | $114,616 | $31,827 |
| 2020 | 71 | 116 | 77 | 3.25 | $23,286 | $7,567 |
| 2019 | 167 | 286 | 80 | 2.10 | $44,969 | $20,430 |
| 2018 | 227 | 391 | 79 | 2.49 | $69,437 | $30,829 |
| 2017 | 140 | 226 | 80 | 2.15 | $41,176 | $18,446 |
| 2016 | 150 | 399 | 75 | 2.21 | $54,613 | $27,552 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Return visit (30+ min) | 88 | $17,336 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 84 | $12,422 | $140 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 145 | $8,113 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 83 | $7,002 | $64 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 11 | $3,712 | $337 |
| Long return visit (40+ min) | 15 | $2,497 | $139 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 12 | $2,382 | $170 |
| New patient visit (30+ min) | 27 | $1,990 | $74 |
| Short return visit (20+ min) | 16 | $1,482 | $67 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $1,025 | $85 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 67 | $749 | $10 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 11 | $530 | $48 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 17 | $187 | $10 |
2022: 12 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 108 | $18,364 | $163 |
| Return visit (30+ min) | 52 | $8,919 | $101 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 117 | $6,626 | $57 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 30 | $6,414 | $200 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 80 | $6,019 | $59 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 15 | $5,688 | $379 |
| Long return visit (40+ min) | 18 | $3,497 | $140 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 13 | $2,310 | $89 |
| New patient visit (30+ min) | 24 | $2,055 | $86 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 15 | $795 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 50 | $593 | $12 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 12 | $225 | None |
2021: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 74 | $7,025 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $6,314 | $166 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 14 | $2,805 | $200 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $2,502 | $86 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 28 | $1,728 | $60 |
| Return visit (30+ min) | 15 | $1,678 | $93 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,648 | $87 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 11 | $126 | $11 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 11 | $115 | $10 |
2020: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 54 | $4,851 | $63 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,217 | $94 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $556 | $35 |
2019: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 101 | $10,108 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $7,347 | $87 |
| Hospital discharge day management, more than 30 minutes | 21 | $1,819 | $87 |
2018: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 165 | $20,586 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 80 | $6,254 | $61 |
| Hospital discharge day management, more than 30 minutes | 34 | $2,923 | $86 |
2017: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 94 | $12,486 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $2,613 | $59 |
| Hospital discharge day management, more than 30 minutes | 26 | $2,364 | $91 |
2016: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 100 | $13,625 | $55 |
| Hospital discharge day management, more than 30 minutes | 45 | $3,874 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,118 | $156 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,264 | $105 |
| Follow-up observation care per day, typically 25 minutes | 18 | $1,177 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $961 | $80 |
| Hospital observation care on day of discharge | 11 | $615 | $56 |
Medicaid work
$494 in 2024
Medicaid paid $494 for 63 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| 1ST HOSP IP/OBS HIGH 75 | 39 | $403 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 24 | $92 |
| 2024 | 63 | 2 | 13 | $494 |
| 2023 | 607 | 5 | 52 | $32,592 |
| 2022 | 219 | 4 | 36 | $12,652 |
| 2021 | 168 | 4 | 39 | $7,400 |
| 2020 | 49 | 1 | 18 | $981 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 267 | $15,545 |
| Return visit (30+ min) | 158 | $6,831 |
| 1ST HOSP IP/OBS HIGH 75 | 68 | $5,525 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 99 | $4,282 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 15 | $408 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 115 | $6,816 |
| 1ST HOSP IP/OBS HIGH 75 | 36 | $2,804 |
| Return visit (30+ min) | 40 | $1,867 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 28 | $1,165 |
2021
| 1ST HOSP IP/OBS HIGH 75 | 26 | $2,693 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 86 | $2,247 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 42 | $2,089 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 14 | $371 |
2020
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 49 | $981 |
Drugs they prescribed that Part D paid
$168,856
Pharmacies billed $168,856 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 967) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
808 generic and 159 brand-name prescriptions · $168,856 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 79 | $89,835 | $1,137 |
| Farxiga | 15 | $16,453 | $1,097 |
| Xarelto | 14 | $13,534 | $967 |
| Jardiance | 11 | $9,996 | $909 |
| Metoprolol | 109 | $1,552 | $14 |
See all 19 drugs
| Eliquis | 79 | $89,835 | $1,137 |
| Farxiga | 15 | $16,453 | $1,097 |
| Xarelto | 14 | $13,534 | $967 |
| Jardiance | 11 | $9,996 | $909 |
| Metoprolol | 109 | $1,552 | $14 |
| Atorvastatin | 115 | $1,043 | $9 |
| Amlodipine Besylate | 93 | $456 | $5 |
| Rosuvastatin | 37 | $424 | $11 |
| Clopidogrel | 58 | $419 | $7 |
| Losartan | 38 | $306 | $8 |
| Lisinopril | 46 | $305 | $7 |
| Amiodarone | 13 | $231 | $18 |
| Carvedilol | 32 | $215 | $7 |
| Simvastatin | 18 | $199 | $11 |
| Furosemide | 44 | $196 | $4 |
| Ezetimibe | 11 | $157 | $14 |
| Metoprolol | 19 | $107 | $6 |
| Hydrochlorothiazide | 30 | $99 | $3 |
| Spironolactone | 23 | $91 | $4 |
Year by year
| 2024 | 967 | 279 | 0% (0) | 16% | $168,856 |
| 2023 | 1,253 | 249 | 0% (0) | 16% | $200,095 |
| 2022 | 752 | 198 | 0% (0) | 13% | $67,975 |
| 2021 | 56 | 26 | 0% (0) | 34% | $8,799 |
| 2020 | 21 | 12 | 0% (0) | None | $2,311 |
| 2018 | 24 | None | 0% (0) | None | $298 |
| 2017 | 22 | 14 | 0% (0) | None | $1,824 |
| 2016 | 55 | 29 | None | None | $2,680 |
| 2015 | 27 | None | 0% (0) | None | $472 |
| 2014 | 61 | 12 | 0% (0) | 31% | $5,075 |
| 2013 | 17 | None | 0% (0) | None | $252 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Eliquis | 128 | $116,789 | $912 |
| Farxiga | 16 | $22,721 | $1,420 |
| Jardiance | 13 | $16,565 | $1,274 |
| Xarelto | 12 | $11,894 | $991 |
| Metoprolol | 165 | $3,126 | $19 |
| Atorvastatin | 107 | $1,312 | $12 |
| Amlodipine Besylate | 137 | $1,263 | $9 |
| Clopidogrel | 84 | $1,070 | $13 |
| Losartan | 44 | $863 | $20 |
| Carvedilol | 66 | $565 | $9 |
| Fenofibrate | 15 | $565 | $38 |
| Lisinopril | 73 | $408 | $6 |
| Hydralazine | 22 | $355 | $16 |
| Amiodarone | 16 | $349 | $22 |
| Hydrochlorothiazide | 59 | $322 | $5 |
| Metoprolol | 49 | $308 | $6 |
| Furosemide | 61 | $301 | $5 |
| Pantoprazole | 19 | $127 | $7 |
| Spironolactone | 14 | $111 | $8 |
| Omeprazole | 11 | $82 | $7 |
| Rosuvastatin | 12 | $20 | $2 |
2022: 17 drugs
| Eliquis | 45 | $35,715 | $794 |
| Entresto | 12 | $8,155 | $680 |
| Metoprolol | 89 | $1,292 | $15 |
| Clopidogrel | 57 | $688 | $12 |
| Isosorbide Dinitrate | 12 | $662 | $55 |
| Atorvastatin | 48 | $651 | $14 |
| Amlodipine Besylate | 108 | $611 | $6 |
| Dilt-Xr | 11 | $522 | $47 |
| Losartan | 42 | $521 | $12 |
| Carvedilol | 60 | $416 | $7 |
| Hydralazine | 14 | $226 | $16 |
| Furosemide | 46 | $167 | $4 |
| Hydrochlorothiazide | 24 | $157 | $7 |
| Lisinopril | 33 | $137 | $4 |
| Metoprolol | 16 | $91 | $6 |
| Spironolactone | 23 | $86 | $4 |
| Pantoprazole | 11 | $66 | $6 |
2018: 1 drug
| Amlodipine Besylate | 12 | $81 | $7 |
Money from drug and device companies
$1,071 in 2025
| 2025 | 6 | 14 | None | $1,071 |
| 2024 | 3 | 30 | None | $4,084 |
| 2023 | 16 | 52 | None | $7,387 |
| 2022 | 6 | 38 | None | $4,612 |
| 2021 | 5 | 28 | None | $2,548 |
| 2020 | 5 | 8 | None | $21,971 |
| 2019 | 6 | 18 | None | $2,530 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | General - Vascular Access | $796 | 7 payments
|
| Medtronic | Corevalve Evolut R | $116 | 1 payment
|
| Inspire Medical Systems | Inspire | $84 | 2 payments
|
| Abbott Laboratories | Mitraclip | $37 | 2 payments
|
| Abiomed | None | $25 | 1 payment
|
| Pfizer | Eliquis | $14 | 1 payment
|
See all 14 published payments
| Boston Scientific | Meals · 2025-12-18 | Watchman Flx | $17 |
| Boston Scientific | Travel · 2025-11-28 | General - Vascular Access | $263 |
| Abiomed | Meals · 2025-11-12 | None | $25 |
| Abbott Laboratories | Meals · 2025-11-12 | Mitraclip | $15 |
| Boston Scientific | Meals · 2025-09-23 | Watchman Flx | $19 |
| Boston Scientific | Meals · 2025-08-23 | General - Vascular Access | $236 |
| Boston Scientific | Travel · 2025-08-22 | General - Vascular Access | $219 |
| Boston Scientific | Travel · 2025-08-22 | General - Vascular Access | $25 |
| Inspire Medical Systems | Meals · 2025-06-26 | Inspire | $44 |
| Inspire Medical Systems | Meals · 2025-05-22 | Inspire | $40 |
| Medtronic | Meals · 2025-04-28 | Corevalve Evolut R | $116 |
| Boston Scientific | Meals · 2025-03-20 | Watchman Flx | $17 |
| Abbott Laboratories | Meals · 2025-03-10 | Mitraclip | $22 |
| Pfizer | Meals · 2025-03-06 | Eliquis | $14 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $4,084
| Medtronic | Onyx Frontier | $2,287 | 20 payments
|
| Abiomed | Impella | $1,772 | 9 payments
|
| Abbott Laboratories | Mitraclip | $26 | 1 payment
|
2023: $7,387
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $4,491 | 12 payments
|
| Medtronic | Corevalve Evolut R | $1,369 | 12 payments
|
| Abiomed | Impella | $710 | 2 payments
|
| Abbott Laboratories | Portico | $232 | 3 payments
|
| Boston Scientific | Watchman Access System | $125 | 3 payments
|
| iRhythm Technologies | Zio Xt Patch | $97 | 5 payments
|
| AngioDynamics | Alphavac | $77 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $53 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $48 | 2 payments
|
| Pfizer | Vyndaqel | $43 | 2 payments
|
| Atricure | Synergy Ablation System | $39 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $35 | 2 payments
|
| Amgen | Repatha | $20 | 1 payment
|
| Esperion Therapeutics | Nexletol | $19 | 1 payment
|
| CVRx | Barostim Neo System | $17 | 1 payment
|
| Novo Nordisk | None | $14 | 1 payment
|
2022: $4,612
| Boston Scientific | Versacross Access Solution | $3,056 | 11 payments
|
| Abbott Laboratories | Mitraclip | $1,282 | 16 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $102 | 5 payments
|
| Medtronic | Avalus | $87 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $43 | 3 payments
|
| Pfizer | Vyndaqel | $41 | 2 payments
|
2021: $2,548
| Edwards Lifesciences | None | $1,716 | 9 payments
|
| Abbott Laboratories | Mitraclip System | $568 | 8 payments
|
| Medtronic | Corevalve Evolut | $114 | 7 payments
|
| Boston Scientific | Synergy | $102 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $47 | 3 payments
|
2020: $21,971
| Medtronic Vascular | Corevalve Evolut | $21,010 | 2 payments
|
| Edwards Lifesciences | None | $854 | 2 payments
|
| Amgen | Repatha | $69 | 2 payments
|
| Abbott Laboratories | Perclose Proglide Suture Mediated Closure System | $24 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $15 | 1 payment
|
2019: $2,530
| Boston Scientific | Crossboss | $2,182 | 11 payments
|
| Astellas Pharma US | Lexiscan | $129 | 3 payments
|
| Pfizer | Vyndaqel | $123 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $69 | 1 payment
|
| Lantheus Medical Imaging | Definity | $15 | 1 payment
|
| Medtronic Vascular | Amplia Mri | $11 | 1 payment
|
Checkups this office reported
9 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 100%That's most of the people this applied to. | 399 |
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 90%That's most of the people this applied to. | 400 |
| Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation TherapyAs Medicare defines this measure | 84% | 111 |
| Cardiac Rehabilitation Patient Referral from an Outpatient SettingAs Medicare defines this measure | 42% | 91 |
| Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF <= 40%)As Medicare defines this measure | 90% | 72 |
| Coronary Artery Disease (CAD): Antiplatelet TherapyAs Medicare defines this measure | 80% | 161 |
| Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control)As Medicare defines this measure | 53% | 62 |
| Medications listed in the chartVisits where the current medication list was documented | 99%That's most of the people this applied to. | 1,190 |
See the other 1 measures
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 100%That's most of the people this applied to. | 655 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
Professional record
- NPI
- 1619226420
- Licence
- CA A134291California A134291: Current · expires 2028-06-30
- Group
- Fresno Community Hospital and Medical Center · Community Foundation Medical Group · Saint Agnes Medical Center
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0011X (207RI0011X); Cardiology (207RC0000X)
- Mailing address
- 5945 Truxtun Ave, Bakersfield, CA, 93309
- NPI first listed
- 2012-09-07
- NPI last updated
- 2023-06-09
- NPI record certified
- 2023-06-09
This is when the NPI record was last certified, not a medical board exam.